What’s Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC detection and compliance, potentially extending patient survival.